2. Academic Validation
  3. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2

Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2

  • Bioorg Med Chem Lett. 2011 Sep 15;21(18):5191-6. doi: 10.1016/j.bmcl.2011.07.056.
Kate S Ashton 1,  David J St Jean Jr,  Steve F Poon,  Matthew R Lee,  John G Allen,  Shiwen Zhang,  Julie A Lofgren,  Xiaoling Zhang,  Christopher Fotsch,  Randall Hungate
Affiliations

Affiliation

  • 1 Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. katea@amgen.com
PMID: 21824779 DOI: 10.1016/j.bmcl.2011.07.056
Abstract

Through the analysis of X-ray crystallographic information and previous SAR studies, a novel series of protein kinase B (PKB/Akt) inhibitors was developed. The compounds showed nanomolar inhibition of Akt1 and were selective against cyclin-dependent kinase 2 (CDK2).

Figures
Products